Email this article Effects of berotek nebuliser treatment on external respiration function, bronchial permeability (BP), hemodynamics (HD), acid-alkaline balance (AAB), oxygen saturation (OS) and their circadian chronostructure in elderly patients with chronic obstructive pulmonary disease
- Authors: Zaslavskaya RM1, Veklenko GV1, Akhmetov KZ.1, Teiblyum MM1
-
Affiliations:
- Issue: Vol 79, No 2 (2004)
- Pages: 55-57
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/29773
- ID: 29773
Cite item
Full Text
Abstract
Aim. To study the effects of nebuliser therapy with berotek on clinical symptoms, external respiration function (ERF), bronchial permeability, hemodynamics and their temporal organisation in elderly patients with chronic obstructive pulmonary disease (COPD).
Material and methods. The study enrolled 20 COPD patients (mean age 64.9 ± 1.9 years) with obstructive respiratory insufficiency of the second-third degree given nebuliser therapy with berotek as adjuvant to conventional treatment (the study group) and 12 COPD patients (mean age 69.7 ± 2.5 years) given only conventional treatment (the control group). The following parameters were examined: ERF, BP, HD, AAB, OS (SaOJ in venous blood before and after treatment. Chronobiological studies of BP and HD were performed for 7 days at the beginning and end of the study. Results. Berotek efficacy manifested on the treatment day 3 as improvement in the symptoms, IRF, BP, a rise in Sa02 and PaC02 and a fall in PaC02 in venous blood. Orcadian chronostructure of peakflowmetry, systolic and diastolic blood pressure, mean arterial pressure persisted. Circaseptal and circasemiseptal rhythms of BP and HD disappeared.
Conclusion. Nebuliser therapy with berotek has a positive effect on clinival symptoms, ERF, BP, gas exchange in the lungs, Sa02, HD and their circadian chronostructure.
Material and methods. The study enrolled 20 COPD patients (mean age 64.9 ± 1.9 years) with obstructive respiratory insufficiency of the second-third degree given nebuliser therapy with berotek as adjuvant to conventional treatment (the study group) and 12 COPD patients (mean age 69.7 ± 2.5 years) given only conventional treatment (the control group). The following parameters were examined: ERF, BP, HD, AAB, OS (SaOJ in venous blood before and after treatment. Chronobiological studies of BP and HD were performed for 7 days at the beginning and end of the study. Results. Berotek efficacy manifested on the treatment day 3 as improvement in the symptoms, IRF, BP, a rise in Sa02 and PaC02 and a fall in PaC02 in venous blood. Orcadian chronostructure of peakflowmetry, systolic and diastolic blood pressure, mean arterial pressure persisted. Circaseptal and circasemiseptal rhythms of BP and HD disappeared.
Conclusion. Nebuliser therapy with berotek has a positive effect on clinival symptoms, ERF, BP, gas exchange in the lungs, Sa02, HD and their circadian chronostructure.
References
- Синопальников А. И. Бронхолитическая терапия больных со стабильным течением хронической обструктивной болезни легких. Рус. мед. журн. 2002; 10 (16): 701-706.
- Чучалин А. Г. и др. (ред) Федеральное руководство для врачей по использованию лекарственных средств (формулярная система). М.; 2002.
- Чучалин А. Г. Хронические обструктивные болезни легких. М.: Бином; 2002.
- Чучалин А. Г. Клинические рекомендации по лечению больных хронической обструктивной болезнью легких. М.; 2002.
- Дворецкий Л. И. Пожилой больной с хроническим обструктивным заболеванием легких в практике интерниста. Рус. мед. журн. 1999; 7 (16): 788-795.
- Цой А. Н., Архипов В. В. Доказательная фармакотерапия хронической обструктивной болезни легких. Consilium medicum 2002; 4 (9): 486-492.
- Friedman M. A multicenter study of nebulizer bronchodilator solutions in chronic obstructive pulmonary disease. Am. J. Med. 1996; 100(1): 30-39.
- Global initiative for chronic obstructive lung disease. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLB/WHO Workshop report Publication 2701. 2001.
- Snow V., Lasber S., Mottar-Pilson С. Ann. Intern. Med. 2001; 134: 595-599.
Supplementary files
